Wang, Qian
Guo, Yicheng http://orcid.org/0000-0001-5357-660X
Liu, Liyuan http://orcid.org/0000-0003-4737-1995
Schwanz, Logan T.
Li, Zhiteng
Nair, Manoj S. http://orcid.org/0000-0002-5994-3957
Ho, Jerren
Zhang, Richard M.
Iketani, Sho http://orcid.org/0000-0002-3733-9556
Yu, Jian
Huang, Yiming http://orcid.org/0000-0003-1932-2803
Qu, Yiming
Valdez, Riccardo
Lauring, Adam S. http://orcid.org/0000-0003-2906-8335
Huang, Yaoxing http://orcid.org/0000-0001-6270-1644
Gordon, Aubree http://orcid.org/0000-0002-9352-7877
Wang, Harris H.
Liu, Lihong http://orcid.org/0000-0003-3128-8513
Ho, David D. http://orcid.org/0000-0003-1627-149X
Article History
Received: 11 September 2023
Accepted: 16 October 2023
First Online: 23 October 2023
Competing interests
: Lihong Liu, S.I., J.Y. and D.D.H. are inventors on a provisional patent application on 10-40 described in this manuscript, titled “Isolation, characterization, and sequences of potent and broadly neutralizing monoclonal antibodies against SARS-CoV-2 and its variants as well as related coronaviruses” (63/271,627). D.D.H. is a co-founder of TaiMed Biologics and RenBio; consultant to WuXi Biologics and Brii Biosciences; and a board director for Vicarious Surgical. A.G. serves on a scientific advisory board for Janssen Pharmaceuticals. The remaining authors declare no competing interests.